Gleostine (Lomustine) Patent Expiration, LOE Window & CMS Spending

Gleostine (Lomustine) by Azurity: Off-Patent Genericized (AB Competition), 1 AB generics, $3.5M 2024 CMS Part D & Medicaid spend, and $6,707 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN017588 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$3.5M
2024 Medicare Part D Spend$3.5M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,707 intro WAC)